126 related articles for article (PubMed ID: 21406230)
1. Worsening of Huntington disease phenotype in CB1 receptor knockout mice.
Mievis S; Blum D; Ledent C
Neurobiol Dis; 2011 Jun; 42(3):524-9. PubMed ID: 21406230
[TBL] [Abstract][Full Text] [Related]
2. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
Blázquez C; Chiarlone A; Sagredo O; Aguado T; Pazos MR; Resel E; Palazuelos J; Julien B; Salazar M; Börner C; Benito C; Carrasco C; Diez-Zaera M; Paoletti P; Díaz-Hernández M; Ruiz C; Sendtner M; Lucas JJ; de Yébenes JG; Marsicano G; Monory K; Lutz B; Romero J; Alberch J; Ginés S; Kraus J; Fernández-Ruiz J; Galve-Roperh I; Guzmán M
Brain; 2011 Jan; 134(Pt 1):119-36. PubMed ID: 20929960
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
Ebert AD; Barber AE; Heins BM; Svendsen CN
Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
[TBL] [Abstract][Full Text] [Related]
4. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
Ramaswamy S; McBride JL; Herzog CD; Brandon E; Gasmi M; Bartus RT; Kordower JH
Neurobiol Dis; 2007 May; 26(2):375-84. PubMed ID: 17336076
[TBL] [Abstract][Full Text] [Related]
5. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
6. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
7. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease.
Mievis S; Blum D; Ledent C
Neurobiol Dis; 2011 Feb; 41(2):570-6. PubMed ID: 21062644
[TBL] [Abstract][Full Text] [Related]
8. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
9. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
Glynn D; Reim K; Brose N; Morton AJ
Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
[TBL] [Abstract][Full Text] [Related]
10. Participation of par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid.
Duan W; Guo Z; Mattson MP
Exp Neurol; 2000 Sep; 165(1):1-11. PubMed ID: 10964480
[TBL] [Abstract][Full Text] [Related]
11. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF.
Puerta E; Hervias I; Barros-Miñones L; Jordan J; Ricobaraza A; Cuadrado-Tejedor M; García-Osta A; Aguirre N
Neurobiol Dis; 2010 May; 38(2):237-45. PubMed ID: 20109548
[TBL] [Abstract][Full Text] [Related]
12. Age-related behavioural phenotype and cellular characterisation of mice with progressive ablation of D1 dopamine receptor-expressing cells.
Babovic D; Jiang L; Gantois I; Lawrence AJ; Ferreri V; Schütz G; Waddington JL; Drago J
Behav Brain Res; 2010 Jan; 206(1):78-87. PubMed ID: 19733597
[TBL] [Abstract][Full Text] [Related]
13. IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats.
Escartin C; Boyer F; Bemelmans AP; Hantraye P; Brouillet E
Neurosci Lett; 2007 Oct; 425(3):167-72. PubMed ID: 17868993
[TBL] [Abstract][Full Text] [Related]
14. In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
Kraft JC; Osterhaus GL; Ortiz AN; Garris PA; Johnson MA
Neuroscience; 2009 Jul; 161(3):940-9. PubMed ID: 19362126
[TBL] [Abstract][Full Text] [Related]
15. Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history.
Diguet E; Fernagut PO; Normand E; Centelles L; Mulle C; Tison F
Neurobiol Dis; 2004 Apr; 15(3):667-75. PubMed ID: 15056475
[TBL] [Abstract][Full Text] [Related]
16. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.
Diguet E; Fernagut PO; Wei X; Du Y; Rouland R; Gross C; Bezard E; Tison F
Eur J Neurosci; 2004 Jun; 19(12):3266-76. PubMed ID: 15217383
[TBL] [Abstract][Full Text] [Related]
17. Alterations in dopamine and benzodiazepine receptor binding precede overt neuronal pathology in mice modelling early Huntington disease pathogenesis.
Kennedy L; Shelbourne PF; Dewar D
Brain Res; 2005 Mar; 1039(1-2):14-21. PubMed ID: 15781041
[TBL] [Abstract][Full Text] [Related]
18. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes.
Ariano MA; Wagle N; Grissell AE
J Neurosci Res; 2005 Jun; 80(5):634-45. PubMed ID: 15880743
[TBL] [Abstract][Full Text] [Related]
19. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains.
McLin JP; Thompson LM; Steward O
Eur J Neurosci; 2006 Dec; 24(11):3134-40. PubMed ID: 17156374
[TBL] [Abstract][Full Text] [Related]
20. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
